



Galectin Therapeutics Inc.
Investor Relations Department
4960 Peachtree Industrial Boulevard,
Suite 240
Norcross, GA 30071
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: GALT

| | |
|---------------|--|
| Last Trade: | 2.46 |
| Trade Time: | 4:00 PM ET Jun 23, 2017 |
| Change: | 0.08 ↑ (3.361%) |
| Day Range | 2.37 - 2.51 |
| 52-Week Range | 0.49 - 3.68 |
| Volume | 175,567 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Corporate Profile

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Jun 21, 2017](#)
[Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics](#)
- [Jun 13, 2017](#)
[Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial](#)
- [Jun 6, 2017](#)
[Autoimmune Disease Patent Granted to Galectin Therapeutics](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- [Mar 28, 2017](#)
[Annual Report \(10-K\)](#)
- [Nov 10, 2016](#)
[Proxy Statement \(DEF 14A\)](#)
- [May 15, 2017](#)
[Quarterly Report \(10-Q\)](#)
- [Nov 8, 2016](#)
[Quarterly Report \(10-Q\)](#)
- [Aug 9, 2016](#)
[Quarterly Report \(10-Q\)](#)